Chronic Osteomyelitis caused by Staphylococcus Aureus: Controlled Clinical Trial of Nafcillin Therapy and Nafcillin-Rifampin Therapy

Carl W. Norden, Richard Bryant, Darwin Palmer, John Z. Montgomerie, Joseph Wheat, Steve M. Jones, Charles B. Bird, Alan I. Hartstein, Robert C. Moellering, Adolf W. Karchmer, Robert C. Aber, Robert Greer, Monto Ho, Allen J. Weinstein, John P. Phair, Merle A. Sande, Gerald L. Mandell, Joshua Fierer, Dale Daniel, William A. CraigJon T. Mader, James A. Reinarz, Chronic Staphylococcal Osteomyelitis Study Group The Chronic Staphylococcal Osteomyelitis Study Group

Research output: Contribution to journalArticlepeer-review

70 Scopus citations

Abstract

A controlled trial of treatment of chronic osteomyelitis caused by Staphylococcus aureus compared nafcillin alone with nafcillin plus rifampin for a six-week period. Treatment was well tolerated, the only adverse effect being mild neutropenia in four of 18 patients; no toxicity was observed from rifampin. Eight of ten patients in the combined treatment group had a favorable clinical response (with follow-up of two to four years) as compared to four of eight in the nafcillin group (P =.2). Despite the failure to show a statistically significant advantage of rifampin plus nafcillin, we conclude that the combination, along with appropriate surgery, should be chronic staphylococcal osteomyelitis.

Original languageEnglish (US)
Pages (from-to)947-951
Number of pages5
JournalSouthern medical journal
Volume79
Issue number8
DOIs
StatePublished - Aug 1986

ASJC Scopus subject areas

  • General Medicine

Fingerprint

Dive into the research topics of 'Chronic Osteomyelitis caused by Staphylococcus Aureus: Controlled Clinical Trial of Nafcillin Therapy and Nafcillin-Rifampin Therapy'. Together they form a unique fingerprint.

Cite this